pindolol sold brand name visken among others nonselective beta blocker used treatment also antagonist serotonin receptor preferentially blocking inhibitory autoreceptors researched addon therapy various antidepressants clomipramine selective serotonin reuptake inhibitors ssris treatment obsessivecompulsive pindolol used hypertension united states canada europe also angina pectoris outside united used alone hypertension pindolol significantly lower blood pressure heart rate evidence base use weak number subjects published studies countries pindolol also used arrhythmias prophylaxis acute stress reactionsmedical citation needed similar propranolol extra contraindication hyperthyroidism patients thyrotoxicosis possible deleterious effects longterm use pindolol adequately appraised betablockade may mask clinical signs continuing hyperthyroidism complications give false impression improvement therefore abrupt withdrawal pindolol may followed exacerbation symptoms hyperthyroidism including thyroid pindolol intrinsic sympathomimetic activity therefore used caution angina pindolol first nonselective beta blocker class Î²adrenergic receptor antagonists receptor level competitive partial agonist possesses intrinsic sympathomimetic activity meaning degree agonist effects absence competing ligands pindolol shows membranestabilizing effects like quinidine possibly accounting antiarrhythmic effects also acts serotonin receptor partial agonist intrinsic activity functional pindolol rapidly well absorbed gi tract undergoes firstpassmetabolization leading oral bioavailability patients uremia may reduced bioavailability food alter bioavailability may increase resorption following oral single dose mg peak plasma concentrations reached within hours effect pindolol pulse rate lowering evident hours despite rather short halflife hours hemodynamic effects persist hours administration plasma halflives increased hours patients renal impairment hours elderly patients hours patients liver cirrhosis approximately pindolol metabolized liver giving hydroxylates found urine gluconurides ethereal sulfates remaining pindolol excreted urine unchanged form pindolol patented sandoz launched us towards end february fda added product drug shortage list stating due shortage active ingredient likely related coronavirus outbreak related supply chain impacts pindolol investigated addon drug antidepressant therapy ssris like fluoxetine treatment depression since rationale behind strategy basis fact pindolol antagonist serotonin presynaptic somatodendritic receptors act inhibitory autoreceptors inhibit serotonin release prodepressive contrast postsynaptic receptors mediate antidepressant blocking autoreceptors doses selective postsynaptic receptors pindolol may able disinhibit serotonin release thereby improve antidepressant effects results augmentation therapy pindolol encouraging early studies low systematic review metaanalysis five randomized controlled trials found overall significant benefit mg although regard patients ssriresistant depression oncedaily highdose pindolol mg qd appears show promising benefit hand systematic review indicated pindolols efficacy demonstrated high evidence initiating pharmacotherapy ssri plus pindolol might accelerate ssris therapeutic pindolols antidepressive efficacy may predominantly result ability desensitize httpsenwikipediaorgwikipindolol